Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.2750 16/02/17
52 week low0.6760 08/12/16
52 week change -0.2000 (-18.18%)
4 week volume224,334,995 27/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Sareum reports maiden profit of £400,000

Sareum, a cancer drug discovery and development company, made a maiden profit after tax on ordinary activities of 400...

Final Results

RNS Number: 9927T Sareum Holdings PLC 19 October 2017 (AIM: SAR) 19 October 2017 Sareum Holdings plc ("Sareum" or "the Company") Final Results Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development company , announces its final results for the year ended 30 June 2017. Operational highlights Lead cancer drug candidate SRA...

Sierra Oncology host KOL Meeting on 12 Oct in NY

RNS Number: 0604T Sareum Holdings PLC 09 October 2017 (AIM: SAR) 9 October 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY Sareum Holdings plc (AIM: SAR) , th...

Sierra Oncology to host call on Chk1 inhibitor

RNS Number: 0247R Sareum Holdings PLC 18 September 2017 (AIM: SAR) 18 September 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September Sareum Holdings plc (AIM: SAR) , the specialist cancer drug discovery an...

Sareum profit after tax anticipated to beat expectations

Sareum said it expects profit for the year after tax and cash at bank, for its results for the year to 30 June 2017, to be ahead...

Pre-Close Trading Statement

RNS Number: 5815O Sareum Holdings PLC 22 August 2017 (AIM: SAR) 22 August 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Pre-Close Trading Statement Sareum Holdings plc (AIM: SAR) , the specialist cancer drug discovery and development business, provides the following trading update ahead of its full year results for the year ending 30 Jun...

Sareum to Present at the ICCS 2017

RNS Number: 3717I Sareum Holdings PLC 19 June 2017 (AIM: SAR) Sareum Holdings PLC ("Sareum" or the "Company") Sareum to Present at the International Cancer Cluster Showcase 2017 Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will deliver a presentation at the 6th annual Internatio...

Sareum updates on Chk1 inhibitor trials

Sareum Holdings has confirmed that it has noted the announcement made today by Sierra Oncology, Inc. reporting on the...

Fundamental DataMore

EPS-0.04
Dividend yield0 %

Latest discussion posts More

  • Re: Good progress & maiden profits

    From 'trendfriend' on FRR - the picture says what I tried to say in words I think. http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=CTcwOoFJTTlWkejW+geWUhtoFp3NOSgnWPFmM8wjkZQ=
    20-Oct-2017
    KALAN
  • Re: Good progress & maiden profits

    Hi HPC - thanks for your SAR tip - had a quick look this morning and will do some more in depth looking later. Adding it to my watchlist. This looks like an excellent company ...
    20-Oct-2017
    KALAN
  • Re: Good progress & maiden profits

    I can only assume that some people wanted more receipts of cash this year; but the drugs seem to work quite well without side effects and have good patent protection for ...
    19-Oct-2017
    HPC Follower

Users' HoldingsMore

Users who hold Sareum Holdings also hold..
RANGE RES.17%
LLOYDS GRP.16%
ROCKHOPPER12%
SOLO OIL12%
SIRIUS MINERALS12%

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR